Navigation Links
ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
Date:5/19/2009

First-in-class Oral Therapeutic for IBD with Novel Mode of Action

MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that data from the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease will be presented in an oral session at the upcoming 2009 Digestive Disease Week (DDW) meeting. Traficet-EN is an orally-available small molecule drug that controls the inappropriate immune system response underlying inflammatory bowel diseases by blocking the CCR9 chemokine receptor. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system. DDW 2009 will be held on May 30 - June 4, 2009, at McCormick Place in Chicago, Illinois.

Satish Keshav, M.D., Ph.D., Department of Gastroenterology, John Radcliffe Hospital, Oxford University, will present Phase II/III clinical trial results from more than 430 patients in the induction phase of the PROTECT-1 study in the following session:

Abstract (#392): PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease

Session/Track: IBD Controlled Clinical Trials - Immunology, Microbiology & Inflammatory Bowel Disease

Location: McCormick Place, Room E450B

Date/Time: Monday, June 1, 2009, 3:30-3:45 PM

About CCX282-B (Traficet-EN)

Traficet-EN is an orally-available small molecule drug which is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking th
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
4. VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
5. Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
6. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
7. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
8. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
9. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
10. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
11. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... Gen-Probe Incorporated (NASDAQ: GPRO ) today reported ... revenues of $135.9 million and non-GAAP earnings per share (EPS) ... APTIMA women,s health products in the second quarter of 2011, ... compared to strong sales a year ago," said Carl Hull, ...
... BioMed Realty Trust, Inc. (NYSE: ... new lease with BIND Biosciences, Inc. at its ... Biosciences, a biopharmaceutical company developing therapeutic targeted nanoparticles ... feet of laboratory and office space. ...
... As the fight over deficit reform continues to drag ... urging lawmakers from across the region to fight to save ... it doesn,t become a victim of short-sighted cuts. ... and medications available to seniors, but would require seniors to ...
Cached Biology Technology:Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property 2BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property 3BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property 4Biotech Group Warns Proposed Medicare Cuts Could Hurt Critical Sector of New England Economy 2
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP ... Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and ... in United States District Court, Middle District of ... on behalf of a class consisting of all ... Provectus securities between December 17, 2013 and May ...
(Date:7/10/2014)... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing ... was interviewed on July 1 st on the Downtown ... Mr. Pereira discusses the company,s next generation smart wallet with ... Wocket™ aims to replace a traditional wallet with a new ... tells Gino he has never heard of the Wocket and ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch ... Asian OEM has selected FPC1021 for a flagship model with ...   FPC is proud to announce this DW ... for start of mass production in August 2014. FPC has ... delivery in the first half of July. The OEM wants ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... CITY, Aug. 31, 2009 Researchers at Huntsman Cancer Institute ... on Ewing,s sarcoma, an often deadly bone cancer that typically ... with poor outcomes have tumors with high levels of a ... chemotherapy. The research is published online today in the journal ...
... its usefulness in counting copies of duplicated genome sequences and ... study to be published Aug. 30 in Nature Genetics ... differ from one person to the next. The researchers ... Search Tool. The study is titled, "Personalized Copy Number and ...
... on the neural mechanisms involved in social behavior, neuroscientists ... the brain structure responsible for our sense of personal ... 30 issue of the journal Nature Neuroscience , ... social distance is an issue. The structure, the ...
Cached Biology News:New hope for deadly childhood bone cancer 2Counting duplicated genome segments now possible 2Counting duplicated genome segments now possible 3Caltech neuroscientists find brain region responsible for our sense of personal space 2Caltech neuroscientists find brain region responsible for our sense of personal space 3Caltech neuroscientists find brain region responsible for our sense of personal space 4
...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Biology Products: